Detection of Pulmonary Embolism in Returning Travelers with Hypoxemic Pneumonia due to COVID-19 in Reunion Island

Larsen, Kevin; Coolen-Allou, Nathalie; Massé, L; Angelino, Alexandre; Allyn, Jérôme; Bruneau, Léa; Maillot, Adrien; Lagrange-Xélot, Marie; Vitry, T.; Meynier, André; Travers, J.-Y.; Foch, Emilie; Allou, Nicolas

doi:10.4269/ajtmh.20-0597

Cited by 11 publications

(19 citation statements)

References 8 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the 66 remaining studies (including 43 studies reporting on ICU patients and 43 studies reporting on non‐ICU hospitalized patients) were included in quantitative data synthesis. 6,16‐81 …”

Section: Resultsmentioning

confidence: 99%

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis

Nopp

Moik

Jilma

et al. 2020

Research and Practice in Thrombosis and Haemostasis

405

388

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis

Nopp

Moik

Jilma

et al. 2020

Research and Practice in Thrombosis and Haemostasis

405

388

View full text Add to dashboard Cite

show abstract

“…The cohort studies included 839 COVID‐19 patients in total, of which 186 developed different types of thrombotic events during the course of infection. 7 , 8 , 9 , 10 , 11 , 12 , 13 …”

Section: Resultsmentioning

confidence: 99%

“…Table 1 summarizes the types of thrombosis reported by the seven studies which included deep vein thrombosis (DVT), 7 , 8 , 9 , 10 , 11 , 12 pulmonary embolism (PE), 10 , 11 , 13 thrombosis in the aortic arch 11 and cerebral thrombosis. 12 …”

Section: Resultsmentioning

confidence: 99%

“…d-Dimer was the only coagulation factor that was consistently significantly higher in the T group as compared to the NT group. [7][8][9][10][11][12][13] Significantly lower platelet count was reported in two studies, 7,12 while only one study reported significantly higher fibrinogen level in the T group as compared to the NT group. 10 Similarly, significantly longer prothrombin time (PT) in the T group was reported by one study.…”

Section: Clinical Datamentioning

confidence: 92%

See 1 more Smart Citation

Systemic inflammation in COVID‐19 patients may induce various types of venous and arterial thrombosis: A systematic review

et al. 2021

View full text Add to dashboard Cite

COVID-19 is a global pandemic with a daily increasing number of affected individuals. Thrombosis is a severe complication of COVID-19 that leads to a worse clinical course with higher rates of mortality. Multiple lines of evidence suggest that hyperinflammation plays a crucial role in disease progression. This review compiles clinical data of COVID-19 patients who developed thrombotic complications to investigate the possible role of hyperinflammation in inducing hypercoagulation. A systematic literature search was performed using PubMed, Embase, Medline and Scopus to identify relevant clinical studies that investigated thrombotic manifestations and reported inflammatory and coagulation biomarkers in COVID-19 patients. Only 54 studies met our inclusion criteria, the majority of which demonstrated significantly elevated inflammatory markers. In the cohort studies with control, D-dimer was significantly higher in COVID-19 patients with thrombosis as compared to the control. Pulmonary embolism, deep vein thrombosis and strokes were frequently reported which could be attributed to the hyperinflammatory response associated with COVID-19 and/or to the direct viral activation of platelets and endothelial cells, two mechanisms that are discussed in this review. It is recommended that all admitted COVID-19 patients should be assessed for hypercoagulation. Furthermore, several studies have suggested that anticoagulation may be beneficial, especially in hospitalized non-ICU patients. Although vaccines against SARS-CoV-2 have been approved and distributed in several countries, research should continue in the field of prevention and treatment of COVID-19 and its severe complications including thrombosis due to the emergence of new variants against which the efficacy of the vaccines is not yet clear.

show abstract

“…Ventura-Díaz et al 20 Espallargas et al 25 Mueller-Peltzer et al 26 Ramadan et al 27 Mouhat et al 30 Alonso-Fernández et al 32 Monfardini et al 39 Freund et al 40 Chen et al 41 Whyte et al 43 Fauvel et al 45 Larsen et al 48 Bavaro et al 51 Mazzaccaro et al 53 Gervaise et al 54 Poyiadji et al 60 Bompard et al 62 BDL Overall (I 2 = 94.8%) patients with severe COVID-19. 68 It has been suggested that SARS-Cov-2 in severe forms of the disease induces an excessive inflammatory state via cytokine storm combined with endothelial injury and pulmonary vascular microthrombosis, which could considerably increase the risk for VTE, mainly PE.…”

Section: Table 1 (Continued)mentioning

confidence: 99%

Venous thromboembolism in COVID-19: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Severe coronavirus disease 2019 (COVID-19) is associated with increased risk of venous thromboembolism events (VTE). This study performed a systematic review in PubMed/EMBASE of studies reporting the prevalence of VTE in patients with COVID-19 who were totally screened/assessed for deep vein thrombosis (DVT) and/or for pulmonary embolism (PE). Among 47 candidate studies ( n = 6459; 33 in Europe), 17 studies ( n = 3973; weighted age 63.0 years, males 60%, intensive care unit (ICU) 16%) reported the prevalence of PE with a pooled estimate of 32% (95% CI: 25, 40%), and 32 studies ( n = 2552; weighted age 62.6 years, males 57%, ICU 49%) reported the prevalence of DVT with a pooled estimate of 27% (95% CI: 21, 34%). A total of 36 studies reported the use of at least prophylactic antithrombotic treatment in the majority of their patients. Meta-regression analysis showed that the prevalence of VTE was higher across studies with a higher percentage of ICU patients and higher study population mean D-dimer values, and lower in studies with mixed dosing of anticoagulation in ⩾ 50% of the population compared to studies with standard prophylactic dosing of anticoagulation in < 50% of the population. The pooled odds ratio for death in patients with COVID-19 and VTE versus those without VTE (17 studies, n = 2882) was 2.1 (95% CI: 1.2, 3.6). Hospitalized patients with severe COVID-19 are at high VTE risk despite prophylactic anticoagulation. Further research should investigate the individualized VTE risk of patients with COVID-19 and the optimal preventive antithrombotic therapy. PROSPERO Registration No.: CRD42020185543.

show abstract

Detection of Pulmonary Embolism in Returning Travelers with Hypoxemic Pneumonia due to COVID-19 in Reunion Island

Cited by 11 publications

References 8 publications

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis

Systemic inflammation in COVID‐19 patients may induce various types of venous and arterial thrombosis: A systematic review

Venous thromboembolism in COVID-19: A systematic review and meta-analysis

Contact Info

Product

Resources

About